Research Papers
Key Research & Review Papers on Swarnaprashan
Published research and review papers on Swarnaprashan. Each link opens the original paper on the publisher's website.
A Critical Appraisal on Swarnaprashana in Children (2014)
A foundational article that reviews the traditional practice from Kashyapa Samhita and discusses its Ayurvedic significance in child development.
Swarna Bindu Prashana: An Ancient Approach to Improve the Infant's Immunity (2020)
Traditional Ayurvedic Measure to Improve Immunity in Children (2024)
A literature-backed review exploring how Swarnaprashan involves gold nanoparticle immunomodulation, microglial activation, cytokine regulation, and vaccine adjuvant potential.
Case Study: Efficacy of Suvarnaprashan on Children’s Health (2023)
Small-scale study with 10 children (ages 0–10), administered monthly for a year, tracking growth (weight, height), appetite, and illness frequency.
Clinical Study: Suvarnaprashan Yoga Effects on Growth & Development (2024)
A literature review highlighting Swarnaprashan’s role in enhancing mental, physical, and immune health among children, and calling for further clinical validation.
Comparative Study: Brahmi Ghrita vs Panchagavya Ghrita-Based Swarnaprashan (2025)
Randomized study with 40 children (0–8 years), comparing efficacy in immunomodulation and physical growth; Group A (Brahmi Ghrita) showed ~66.7% relief vs ~55.7% in Group B.
Systematic Review: Gold Formulations (Including Swarnaprashan) (2025)
Review of 15 studies involving gold-based Ayurvedic interventions. Parameters like immunity, intelligence, and growth showed positive outcomes without adverse reactions.
Narrative Review: Immunity & Cognition Effects of Swarnaprashan (2023)
Reviews existing publications to conclude Swarnaprashan is safe and effective for cognitive enhancement, immune protection, and child growth.
Clinical Study: Growth, Nutrition & Morbidity in 0–5-Year-Olds (2025)
A randomized study of 200 children in Jodhpur district. Reported ~68.7% improvement in growth and nutritional parameters and a 41.7% reduction in morbidity (p < 0.05).
Immunomodulatory Clinical Evaluation – Phase II (2024)
Prospective interventional open-label study on 30 children (2–5 years) over 8 weeks. Swarnaprashan significantly improved immunological (IgG, IgM, C3, C4), hematological, and quality-of-life parameters with good safety.
Observational Study in Pediatrics (0–16 years) (2024)
Case study with 30 children over 6 months; reported benefits in physical strength, metabolism, immunity, intelligence, digestion, complexion, and fertility.
Effect on Intelligence Quotient (IQ) in School Children (2024)
Study with 60 children (ages 6–15) for 30 days. IQ increased from a mean of 99.05 to 118.37 (~19.5% improvement; p < 0.05).